<DOC>
	<DOCNO>NCT02494206</DOCNO>
	<brief_summary>The purpose study assess efficacy QBX258 , compound develop Novartis Corporation compose two antibody , reduce arm volume excess woman stage I-II breast cancer relate lymphedema .</brief_summary>
	<brief_title>Immunotherapy Treatment Breast Cancer Related Upper Extremity Lymphedema ( BCRL )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lymphedema</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Women 1870 unilateral stage I II BCRL Volume difference least 300 mL normal lymphedematous limb base perometry evaluation BMI 1830 No current evidence breast cancer At least 6 month postop axillary lymph node dissection Bilateral lymphedema history bilateral axillary lymph node dissection Recent history cellulitis affect extremity ( within last 3 month ) Recurrent breast cancer malignancy Current ( within last month ) use chemotherapy breast malignancy Current ( within last 3 month ) use radiation breast malignancy Recent ( within last month ) current intensive MLD and/or short stretch bandage use Unstable lymphedema ( i.e . worsen symptoms/measurements past 3 month ) Pregnant nursing ( lactate ) woman Stage III lymphedema Patients take acetaminophen ( paracetamol ) chronically , i.e . 1 g/day 3 7 day , 2 g/ day 1 day 7 day Use investigational drug time enrollment , within 30 day 5 halflives enrollment , whichever long History hypersensitivity study drug drug similar chemical class ( e.g . monoclonal antibody , polyclonal gamma globulin , polysorbates ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>QBX258</keyword>
	<keyword>human monoclonal antibody</keyword>
	<keyword>VAK694</keyword>
	<keyword>QAX576</keyword>
	<keyword>15-085</keyword>
</DOC>